Mekinist

Trametinib, the active ingredient in Mekinist, is a MEK inhibitor presented as a tablet for oral use. It targets cancers that harbor BRAF V600E/K mutations, specifically metastatic melanoma and certain non‑small cell lung cancers. GNH USA supplies Mekinist as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Mekinist acts on the MAPK/ERK signaling pathway in tumors with BRAF mutations. - Metastatic melanoma with BRAF V600E/K mutation: improves progression‑free and overall survival in patients with this genetic profile. - Non‑small cell lung cancer with BRAF V600E mutation: provides targeted inhibition of tumor growth in this subset of lung cancer. - Combination therapy with dabrafenib for BRAF‑mutated melanoma: enhances response rates when used together with a BRAF inhibitor.

Common Side Effects: - Rash: mild to moderate skin irritation. - Diarrhea: watery stools, may lead to dehydration. - Fatigue: persistent tiredness affecting daily activities. - Nausea: sensation of needing to vomit. - Edema: swelling of extremities. - Acneiform dermatitis: pimples resembling acne.

Serious or Rare Side Effects: - Interstitial lung disease: inflammation of lung tissue requiring immediate medical attention. - Cardiomyopathy: reduced heart function that may lead to heart failure. - Retinal disorders: visual disturbances including blurred vision or retinal vein occlusion. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Severe infections: opportunistic infections due to immune modulation.

Before initiating therapy, clinicians should evaluate baseline organ function and monitor throughout treatment. - Cardiac monitoring: assess ejection fraction prior to and during therapy. - Liver function tests: check ALT, AST, and bilirubin regularly. - Ocular assessment: perform baseline eye exam and monitor for visual changes. - Renal impairment: use with caution in patients with severe renal dysfunction. - Pregnancy and lactation: safety unknown; avoid unless benefit outweighs risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Trametinib may interact with several co‑administered medicines, requiring dose adjustments or monitoring. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce trametinib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase trametinib plasma levels and toxicity. - Concurrent use with other MEK inhibitors: additive toxicity risk. Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): potential increase in bleeding risk. - QT‑prolonging agents: monitor ECG for arrhythmias. - Immunosuppressants (e.g., cyclosporine): may alter trametinib metabolism.